Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.

OBJECTIVE There are significant unmet needs in the treatment of schizophrenia, especially for the treatment of cognitive impairment, negative syndrome, and cognitive function. Preclinical data suggest that agonists with selective affinity for acetylcholine muscarinic receptors provide a potentially new mechanism to treat schizophrenia. The authors studied xanomeline, a relatively selective muscarinic type 1 and type 4 (M(1) and M(4)) receptor agonist, to determine if this agent is effective in the treatment of schizophrenia. METHOD In this pilot study, the authors examined the efficacy of xanomeline on clinical outcomes in subjects with schizophrenia (N=20) utilizing a double-blind, placebo-controlled, 4-week treatment design. Outcome measures included the Positive and Negative Syndrome Scale (PANSS) for schizophrenia, the Brief Psychiatric Rating Scale (BPRS), the Clinical Global Impression (CGI) scale, and a test battery designed to measure cognitive function in patients with schizophrenia. RESULTS Subjects treated with xanomeline did significantly better than subjects in the placebo group on total BPRS scores and total PANSS scores. In the cognitive test battery, subjects in the xanomeline group showed improvements most robustly in measures of verbal learning and short-term memory function. CONCLUSIONS These results support further investigation of xanomeline as a novel approach to treating schizophrenia.

[1]  A. Levey,et al.  Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[2]  K. Perry,et al.  The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex , 2001, Biological Psychiatry.

[3]  M. Bohus,et al.  Cholinergic REM induction test: muscarinic supersensitivity underlies polysomnographic findings in both depression and schizophrenia. , 1994, Journal of psychiatric research.

[4]  Alcino J. Silva,et al.  Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice , 2003, Nature Neuroscience.

[5]  Jeremy M Crook,et al.  Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation , 2000, Biological Psychiatry.

[6]  B. Dean,et al.  Muscarinic1 and 2 receptor mRNA in the human caudate-putamen: no change in m1 mRNA in schizophrenia , 2000, Molecular Psychiatry.

[7]  J. Wess,et al.  Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Wess,et al.  M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related central nervous system pathologies , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  J. Yeomans.  Role of Tegmental Cholinergic Neurons in Dopaminergic Activation, Antimuscarinic Psychosis and Schizophrenia , 1995, Neuropsychopharmacology.

[10]  R. Tandon,et al.  Muscarinic cholinergic hyperactivity in schizophrenia relationship to positive and negative symptoms , 1991, Schizophrenia Research.

[11]  K. Behnke,et al.  The Brief Psychiatric Rating Scale. Dimension of schizophrenia--reliability and construct validity. , 1989, Psychopathology.

[12]  Jeffrey A. Lieberman,et al.  Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder , 2002 .

[13]  J. Wess,et al.  Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[14]  The CATIE schizophrenia effectiveness trial , 2005, Schizophrenia Research.

[15]  D. Price,et al.  Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[16]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[17]  F. Bymaster,et al.  Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. , 1999, The Journal of pharmacology and experimental therapeutics.

[18]  D. Wong,et al.  Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. , 1994, The Journal of pharmacology and experimental therapeutics.

[19]  J. Friedman,et al.  Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists , 2004, Psychopharmacology.

[20]  F. Bymaster,et al.  Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents , 2002, Molecular Psychiatry.

[21]  F. Bymaster,et al.  Therapeutic opportunities for muscarinic receptors in the central nervous system. , 2000, Journal of medicinal chemistry.

[22]  W W Offen,et al.  Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. , 1997, Archives of neurology.

[23]  D L Braff,et al.  Sensorimotor gating and schizophrenia. Human and animal model studies. , 1990, Archives of general psychiatry.

[24]  J. Lieberman,et al.  Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs , 2005, Molecular Psychiatry.

[25]  T. Werge,et al.  The Muscarinic M1/M4 Receptor Agonist Xanomeline Exhibits Antipsychotic-Like Activity in Cebus apella Monkeys , 2003, Neuropsychopharmacology.

[26]  W. Fenton,et al.  Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia , 2004, Schizophrenia Research.

[27]  Michael F. Green,et al.  Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study , 2003, Psychopharmacology.

[28]  T. Barnes.  A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.

[29]  T. Manabe,et al.  Mice Lacking M2 and M3 Muscarinic Acetylcholine Receptors Are Devoid of Cholinergic Smooth Muscle Contractions But Still Viable , 2002, The Journal of Neuroscience.

[30]  B. Dean,et al.  Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. , 2001, The American journal of psychiatry.

[31]  S. Lightowler,et al.  The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. , 2001, The Journal of pharmacology and experimental therapeutics.

[32]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[33]  D. Middlemiss,et al.  Functional effects of the muscarinic receptor agonist, xanomeline, at 5‐HT1 and 5‐HT2 receptors , 1998, British journal of pharmacology.

[34]  S. Snyder.  The dopamine connection , 1990, Nature.

[35]  Peter B. Jones,et al.  The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia , 2003, Acta psychiatrica Scandinavica. Supplementum.